Clinics in Dermatology
Volume 24, Issue 4 , Pages 247-255 , July 2006

Dermatologic aspects of thyroid disease

  • Kenneth D. Burman, MD

      Affiliations

    • Endocrine Section and Department of Medicine, Washington Hospital Center, Washington, DC 20010, USA
    • Department of Medicine, Georgetown University, Washington, DC 20007, USA
    • Corresponding Author InformationCorresponding author. Section of Endocrinology WHC, Washington, DC 20010, USA. Tel.: +1 202 8776563; fax: +1 202 8776588.
    • ,
  • Lynn McKinley-Grant, MD

      Affiliations

    • Dermatology Department, Washington Hospital Center, Washington, DC 20010, USA
    • George Washington University Medical Center, Washington, DC 20052, USA

References 

  1. Jabbour SA. Cutaneous manifestations of endocrine disorders: a guide for dermatologists. Am J Clin Dermatol. 2003;4:315–331
  2. Leonhardt JM, Heymann WR. Thyroid disease and the skin. Dermatol Clin 2002;20:473-81, vii.
  3. Burman K. Hyperthyroidism, Chapter 41. In:  Becker KA editors. Principles and practice of endocrinology and metabolism. 2nd ed.. Philadelphia (Pa): J.B. Lippincott; 1995;p. 367–385
  4. Weiss RE, Hayashi Y, Nagaya T, et al. Dominant inheritance of resistance to thyroid hormone not linked to defects in the thyroid hormone receptor alpha or beta genes may be due to a defective cofactor. [see comments] J Clin Endocrinol Metab. 1996;81:4196–4203
  5. Mazzaferri EL, Surks MI. Recognizing the faces of hypothyroidism. Hosp Pract (Off Ed). 1999;34:93–96
  6. Col NF, Surks MI, Daniels GH. Subclinical thyroid disease: clinical applications. JAMA. 2004;291:239–243
  7. Surks MI, Ortiz E, Daniels GH, et al. Subclinical thyroid disease: scientific review and guidelines for diagnosis and management. JAMA. 2004;291:228–238
  8. Burman KD, Cooper DS. The diagnostic evaluation and management of hyperthyroidism due to Graves' disease, toxic nodules and toxic multinodular goiter. In:  Cooper DS editors. New York: Marcel Dekker, Inc; 2001;p. 33–92
  9. Lu R, Burman KD, Jonklaas J. Transient Graves' hyperthyroidism during pregnancy in a patient with Hashimoto's hypothyroidism. Thyroid. 2005;15:725–729
  10. Solomon BL, Wartofsky L, Burman KD. Current trends in the management of well differentiated papillary thyroid carcinoma. J Clin Endocrinol Metab. 1996;81:333–339
  11. Niepomniszcze H, Amad RH. Skin disorders and thyroid diseases. J Endocrinol Invest. 2001;24:628–638
  12. Rotella CM, Alvarez F, Kohn LD, Toccafondi R. Graves' autoantibodies to extrathyroidal TSH receptor: their role in ophthalmopathy and pretibial myxedema. Acta Endocrinol Suppl (Copenh). 1987;281:344–347
  13. Chavis PS. Thyroid and the eye. Curr Opin Ophthalmol. 2002;13:352–356
  14. Fatourechi V. Pretibial myxedema: pathophysiology and treatment options. Am J Clin Dermatol. 2005;6:295–309
  15. Fatourechi V, Ahmed DD, Schwartz KM. Thyroid acropachy: report of 40 patients treated at a single institution in a 26-year period. J Clin Endocrinol Metab. 2002;87:5435–5441
  16. Fatourechi V, Aniszewski JP, Fatourechi GZ, Atkinson EJ, Jacobsen SJ. Clinical features and outcome of subacute thyroiditis in an incidence cohort: Olmsted County, Minnesota, study. J Clin Endocrinol Metab. 2003;88:2100–2105
  17. De Bruin TW, L.E. , Brown RS. Heterogeneity of TSH receptor-binding antibodies in Hashimoto's thyroiditis and Graves' disease. Am J Med Sci. 1990;299:291–297
  18. Di Cerbo A, Di Paola R, Menzaghi C, et al. Graves' immunoglobulins activate phospholipase A2 by recognizing specific epitopes on thyrotropin receptor. J Clin Endocrinol Metab. 1999;84:3283–3292
  19. Bahn RS. TSH receptor expression in orbital tissue and its role in the pathogenesis of Graves' ophthalmopathy. J Endocrinol Invest. 2004;27:216–220
  20. Bahn RS, Heufelder AE. Pathogenesis of Graves' ophthalmopathy. N Engl J Med. 1993;329:1468–1475
  21. Kohar YM, Tan KC. Preradial myxedema: a case report. Ann Acad Med Singapore. 1996;25:281–282
  22. Wortsman J, Dietrich J, Traycoff RB, Stone S. Preradial myxedema in thyroid disease. Arch Dermatol. 1981;117:635–638
  23. Evans TC. Thyroid disease. Prim Care. 2003;30:625–640
  24. Leovey A, Sztojka I, Paragh G, Mohacsi A. Atypical clinical features of hypo- and hyperthyroidism in elderly age. Ther Hung. 1991;39:167–174
  25. Stathatos N, Wartofsky L. The euthyroid sick syndrome: is there a physiologic rationale for thyroid hormone treatment?. J Endocrinol Invest. 2003;26:1174–1179
  26. Wartofsky L, Burman KD. Alterations in thyroid function in patients with systemic illness: the euthyroid sick syndrome. Endocr Rev. 1982;3:164–217
  27. Weetman AP, et al. The production and characterization of thyroid-derived T-cell lines in Graves' disease and Hashimoto's thyroiditis. Clin Immunol Immunopathol. 1986;39:139–150
  28. Endo T, Kogai T, Nakazato M, et al. Autoantibody against Na+/I− symporter in the sera of patients with autoimmune thyroid disease. Biochem Biophys Res Commun. 1996;224:92–95
  29. Jansson R, Totterman TH, Sallstrom J, Dahlberg P. Thyroid-infiltrating T lymphocyte subsets in Hashimoto's thyroiditis. J Clin Endocrinol Metab. 1983;56:1164–1168
  30. Kohn LD, Suzuki K, Hoffman WH, et al. Characterization of monoclonal thyroid-stimulating and thyrotropin binding-inhibiting autoantibodies from a Hashimoto's patient whose children had intrauterine and neonatal thyroid disease. J Clin Endocrinol Metab. 1997;82:3998–4009
  31. Ai J, Leonhardt JM, Heymann WR. Autoimmune thyroid diseases: etiology, pathogenesis, and dermatologic manifestations. J Am Acad Dermatol. 2003;48:641–659[quiz 660-2]
  32. Akamizu T, Kohn LD, Hiratani H, et al. Hashimoto's thyroiditis with heterogeneous antithyrotropin receptor antibodies: unique epitopes may contribute to the regulation of thyroid function by the antibodies. J Clin Endocrinol Metab. 2000;85:2116–2121
  33. Wang SA, Rahemtullah A, Faquin WC, et al. Hodgkin's lymphoma of the thyroid: a clinicopathologic study of five cases and review of the literature. Mod Pathol. 2005;
  34. Slatosky J, Shipton B, Wahba H. Thyroiditis: differential diagnosis and management. Am Fam Physician. 2000;61:1047–1052
  35. Lucas A, Pizarro E, Granada ML, et al. Postpartum thyroiditis: long-term follow-up. Thyroid. 2005;15:1177–1181
  36. Stagnaro-Green A. Recognizing, understanding, and treating postpartum thyroiditis. Endocrinol Metab Clin North Am 2000;29:417-30, ix.
  37. Stagnaro-Green A. Clinical review 152: postpartum thyroiditis. J Clin Endocrinol Metab. 2002;87:4042–4047
  38. Stagnaro-Green A. Postpartum thyroiditis. Best Pract Res Clin Endocrinol Metab. 2004;18:303–316
  39. Stagnaro-Green A, Glinoer D. Thyroid autoimmunity and the risk of miscarriage. Best Pract Res Clin Endocrinol Metab. 2004;18:167–181
  40. Bartley GB. The epidemiologic characteristics and clinical course of ophthalmopathy associated with autoimmune thyroid disease in Olmsted County, Minnesota. Trans Am Ophthalmol Soc. 1994;92:477–588
  41. Bartley GB, Fatourechi V, Kadrmas EF, et al. Clinical features of Graves' ophthalmopathy in an incidence cohort. Am J Ophthalmol. 1996;121:284–290
  42. Lu R, et al. Oxygen free radicals in interleukin-1beta–induced glycosaminoglycan production by retro-ocular fibroblasts from normal subjects and Graves' ophthalmopathy patients. Thyroid. 1999;9:297–303
  43. K.D. Burman. Thyroid disease and osteoporosis. Hosp Pract (Off Ed) 1997;32:71-3, 78-85; discussion 85-6.
  44. Burch HB, Wartofsky L. Graves' ophthalmopathy: current concepts regarding pathogenesis and management. Endocr Rev. 1993;14:747–793[Review]
  45. Higuchi R, Kumagai T, Kobayashi M, et al. Short-term hyperthyroidism followed by transient pituitary hypothyroidism in a very low birth weight infant born to a mother with uncontrolled Graves' disease. Pediatrics. 2001;107:E57
  46. Grant DB, Smith I, Fuggle PW, Tokar S, Chapple J. Congenital hypothyroidism detected by neonatal screening: relationship between biochemical severity and early clinical features. Arch Dis Child. 1992;67:87–90
  47. LaFranchi S. Congenital hypothyroidism: etiologies, diagnosis, and management. Thyroid. 1999;9:735–740
  48. Podkrajsek KT, Bratanic N, Krzisnik C, Battelino T. Autoimmune regulator-1 messenger ribonucleic acid analysis in a novel intronic mutation and two additional novel AIRE gene mutations in a cohort of autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy patients. J Clin Endocrinol Metab. 2005;90:4930–4935
  49. Burman KD. Is long-term levothyroxine therapy safe?. Arch Intern Med. 1990;150:2010–2013
  50. Ain KB, Pucino F, Shiver TM, Banks SM. Thyroid hormone levels affected by time of blood sampling in thyroxine-treated patients. Thyroid. 1993;3:82–85
  51. Hennessey JV, Evaul JE, Tseng YC, Burman KD, Wartofsky L. l-Thyroxine dosage: a reevaluation of therapy with contemporary preparations. Ann Intern Med. 1986;105:11–15
  52. Dickey RA, Wartofsky L, Feld S. Optimal thyrotropin level: normal ranges and reference intervals are not equivalent. Thyroid. 2005;15:1035–1039
  53. Wartofsky L. Update in endocrinology. Ann Intern Med. 2005;143:673–682
  54. Wartofsky L. Levothyroxine therapy for hypothyroidism: should we abandon conservative dosage titration?. Arch Intern Med. 2005;165:1683–1684
  55. Wartofsky L, Dickey RA. The evidence for a narrower thyrotropin reference range is compelling. J Clin Endocrinol Metab. 2005;90:5483–5488
  56. Mazzaferri EL, Robbins RJ, Spencer CA, et al. A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma. J Clin Endocrinol Metab. 2003;88:1433–1441
  57. Mazzaferri EL, Massoll N. Management of papillary and follicular (differentiated) thyroid cancer: new paradigms using recombinant human thyrotropin. Endocr Relat Cancer. 2002;9:227–247
  58. Yip L, Cote GJ, Shapiro SE, et al. Multiple endocrine neoplasia type 2: evaluation of the genotype-phenotype relationship. Arch Surg. 2003;138:409–416[discussion 416]
  59. Ain KB. Management of undifferentiated thyroid cancer. Baillieres Best Pract Res Clin Endocrinol Metab. 2000;14:615–629
  60. Pedersen RK, Pedersen NT. Primary non-Hodgkin's lymphoma of the thyroid gland: a population based study. Histopathology. 1996;28:25–32
  61. Solomon BL, et al. Current trends in the management of well differentiated papillary thyroid carcinoma. J Clin Endocrinol Metab. 1996;81:333–339
  62. Wartofsky L. Management of low-risk well-differentiated thyroid cancer based only on thyroglobulin measurement after recombinant human thyrotropin. Thyroid. 2002;12:583–590
  63. Burman KD, Ringel MD, Wartofsky L. Unusual types of thyroid neoplasms. Endocrinol Metab Clin North Am. 1996;25:49–68
  64. Burningham AR, Krishnan J, Davidson BJ, Ringel MD, Burman KD. Papillary and follicular variant of papillary carcinoma of the thyroid: initial presentation and response to therapy. Otolaryngol Head Neck Surg. 2005;132:840–844
  65. Newkirk KA, Ringel MD, Jelinek J, et al. Ultrasound-guided fine-needle aspiration and thyroid disease. Otolaryngol Head Neck Surg. 2000;123:700–705
  66. Wartofsky L. Using baseline and recombinant human TSH-stimulated Tg measurements to manage thyroid cancer without diagnostic (131)I scanning. J Clin Endocrinol Metab. 2002;87:1486–1489
  67. Alwaheeb S, Ghazarian D, Boerner SL, Asa SL. Cutaneous manifestations of thyroid cancer: a report of four cases and review of the literature. J Clin Pathol. 2004;57:435–438
  68. Avram AM, Gielczyk R, Su L, Vine AK, Sisson JC. Choroidal and skin metastases from papillary thyroid cancer: case and a review of the literature. J Clin Endocrinol Metab. 2004;89:5303–5307
  69. Azoulay S, Adem C, Pelletier FL, et al. Skin metastases from unknown origin: role of immunohistochemistry in the evaluation of cutaneous metastases of carcinoma of unknown origin. J Cutan Pathol. 2005;32:561–566
  70. Kumar PV, Monabati A, Tabei SZ, et al. Metastatic follicular thyroid carcinoma diagnosed by fine needle aspiration cytology: a report of 3 cases. Acta Cytol. 2005;49:177–180
  71. Mahalingam M, Bhawan J. Metastatic papillary carcinoma of the thyroid. J Cutan Pathol. 2004;31:509–512
  72. Mishra A, Samant DD, Krishnani N, Saroj KM. Unusual distant metastases from papillary thyroid carcinoma. J Assoc Physicians India. 2002;50:1338
  73. Angerpointner TA. Management of patients with hereditary medullary thyroid carcinoma. J Pediatr Surg. 2005;40:1214
  74. Carling T. Multiple endocrine neoplasia syndrome: genetic basis for clinical management. Curr Opin Oncol. 2005;17:7–12
  75. Dannenberg H, Komminoth P, Dinjens WN, Speel EJ, de Krijger RR. Molecular genetic alterations in adrenal and extra-adrenal pheochromocytomas and paragangliomas. Endocr Pathol. 2003;14:329–350
  76. de Krijger RR. Endocrine tumor syndromes in infancy and childhood. Endocr Pathol. 2004;15:223–226
  77. Fitze G. Management of patients with hereditary medullary thyroid carcinoma. Eur J Pediatr Surg. 2004;14:375–383
  78. Jimenez C, Gagel RF. Genetic testing in endocrinology: lessons learned from experience with multiple endocrine neoplasia type 2 (MEN2). Growth Horm IGF Res. 2004;14(Suppl A):S150–S157
  79. Koch CA. Molecular pathogenesis of MEN2-associated tumors. Fam Cancer. 2005;4:3–7
  80. Massoll N, Mazzaferri EL. Diagnosis and management of medullary thyroid carcinoma. Clin Lab Med. 2004;24:49–83
  81. Brauckhoff M, Gimm O, Weiss CL, et al. Multiple endocrine neoplasia 2B syndrome due to codon 918 mutation: clinical manifestation and course in early and late onset disease. World J Surg. 2004;28:1305–1311
  82. Chang A, Chan WF, Lo CY, Lam KS. Multiple endocrine neoplasia type 2B in a Chinese patient. Hong Kong Med J. 2004;10:206–209
  83. Kameyama K, Okinaga H, Takami H. Clinical manifestations of familial medullary thyroid carcinoma. Biomed Pharmacother. 2004;58:348–350
  84. Zhang YF, Hong J, Zhao YJ, et al. Multiple endocrine neoplasia type 2B caused by a single point mutation in RET proto-oncogene in a Chinese patient. Chin Med J (Engl). 2004;117:1262–1264
  85. Holloway KB, Flowers FP. Multiple endocrine neoplasia 2B (MEN 2B)/MEN 3. Dermatol Clin. 1995;13:99–103
  86. Lora MS, Waguespack SG, Moley JF, Walvoord EC. Adrenal ganglioneuromas in children with multiple endocrine neoplasia type 2: a report of two cases. J Clin Endocrinol Metab. 2005;90:4383–4387
  87. Sweetser DA, Froelick GJ, Matsumoto AM, et al. Ganglioneuromas and renal anomalies are induced by activated RET(MEN2B) in transgenic mice. Oncogene. 1999;18:877–886
  88. Bauer AJ, Stratakis CA. The lentiginoses: cutaneous markers of systemic disease and a window to new aspects of tumourigenesis. J Med Genet. 2005;42:801–810
  89. Bourdeau I, Lacroix A, Schurch W, et al. Primary pigmented nodular adrenocortical disease: paradoxical responses of cortisol secretion to dexamethasone occur in vitro and are associated with increased expression of the glucocorticoid receptor. J Clin Endocrinol Metab. 2003;88:3931–3937
  90. Robinson-White A, Hundley TR, Shiferaw M, et al. Protein kinase-A activity in PRKAR1A-mutant cells, and regulation of mitogen-activated protein kinases ERK1/2. Hum Mol Genet. 2003;12:1475–1484
  91. Sandrini F, Stratakis C. Clinical and molecular genetics of primary pigmented nodular adrenocortical disease. Arq Bras Endocrinol Metabol. 2004;48:637–641
  92. Stratakis CA, Matyakhina L, Courkoutsakis N, et al. Pathology and molecular genetics of the pituitary gland in patients with the ‘complex of spotty skin pigmentation, myxomas, endocrine overactivity and schwannomas’ (Carney complex). Front Horm Res. 2004;32:253–264
  93. McDonnell JK. Cardiac disease and the skin. Dermatol Clin 2002;20:503-11, vii.
  94. Kato N, Kimura K, Sugawara H, et al. Germline mutation of the PTEN gene in a Japanese patient with Cowden's disease. Int J Oncol. 2001;18:1017–1022
  95. Reifenberger J, Rauch L, Beckmann MW, et al. Cowden's disease: clinical and molecular genetic findings in a patient with a novel PTEN germline mutation. Br J Dermatol. 2003;148:1040–1046
  96. Wirtzfeld DA, Petrelli NJ, Rodriguez-Bigas MA. Hamartomatous polyposis syndromes: molecular genetics, neoplastic risk, and surveillance recommendations. Ann Surg Oncol. 2001;8:319–327
  97. Eng C. Molecular basis of thyroid cancer: molecular basis of thyroid cancer. Thyroid. 2005;15:1109
  98. Allen BS, Fitch MH, Smith JG. Multiple hamartoma syndrome. A report of a new case with associated carcinoma of the uterine cervix and angioid streaks of the eyes. J Am Acad Dermatol. 1980;2:303–308
  99. Prabhu SS, Aldape KD, Bruner JM, Weinberg JS. Cowden disease with Lhermitte-Duclos disease: case report. Can J Neurol Sci. 2004;31:542–549
  100. Haibach H, et al. Multiple hamartoma syndrome (Cowden's disease) associated with renal cell carcinoma and primary neuroendocrine carcinoma of the skin (Merkel cell carcinoma). Am J Clin Pathol. 1992;97:705–712
  101. Marsh DJ, Dahia PL, Caron S, et al. Germline PTEN mutations in Cowden syndrome–like families. J Med Genet. 1998;35:881–885
  102. Perez-Nunez A, Lagares A, Benitez J, et al. Lhermitte-Duclos disease and Cowden disease: clinical and genetic study in five patients with Lhermitte-Duclos disease and literature review. Acta Neurochir (Wien). 2004;146:679–690
  103. Burman K, Becker K, Cytryn A, Goodglick T. Thyroid diseases. In:  Korenman SG editors. The Atlas of Clinical Endocrinology, Philadelphia: Current Medicine, Inc. Blackwell Publishers; 1999;

PII: S0738-081X(06)00051-4

doi: 10.1016/j.clindermatol.2006.04.010

Clinics in Dermatology
Volume 24, Issue 4 , Pages 247-255 , July 2006

Article Tools

* Image Usage & Resolution